JP2022513933A5 - - Google Patents
Info
- Publication number
- JP2022513933A5 JP2022513933A5 JP2021534641A JP2021534641A JP2022513933A5 JP 2022513933 A5 JP2022513933 A5 JP 2022513933A5 JP 2021534641 A JP2021534641 A JP 2021534641A JP 2021534641 A JP2021534641 A JP 2021534641A JP 2022513933 A5 JP2022513933 A5 JP 2022513933A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862780703P | 2018-12-17 | 2018-12-17 | |
| US62/780,703 | 2018-12-17 | ||
| PCT/US2019/066923 WO2020131918A1 (en) | 2018-12-17 | 2019-12-17 | Organic compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513933A JP2022513933A (ja) | 2022-02-09 |
| JP2022513933A5 true JP2022513933A5 (https=) | 2022-12-23 |
| JPWO2020131918A5 JPWO2020131918A5 (https=) | 2022-12-23 |
| JP7645797B2 JP7645797B2 (ja) | 2025-03-14 |
Family
ID=71100855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534641A Active JP7645797B2 (ja) | 2018-12-17 | 2019-12-17 | 有機化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12325726B2 (https=) |
| EP (1) | EP3897656A4 (https=) |
| JP (1) | JP7645797B2 (https=) |
| KR (1) | KR102931436B1 (https=) |
| CN (1) | CN113226326B (https=) |
| AU (1) | AU2019406803B2 (https=) |
| BR (1) | BR112021011765A2 (https=) |
| CA (1) | CA3121636A1 (https=) |
| IL (1) | IL283960B2 (https=) |
| MX (1) | MX2021007142A (https=) |
| WO (1) | WO2020131918A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| AU2019406803B2 (en) | 2018-12-17 | 2025-04-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2021168106A1 (en) * | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| JP2023539125A (ja) * | 2020-08-20 | 2023-09-13 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2023159094A2 (en) * | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| KR100338287B1 (ko) | 1994-02-14 | 2002-11-30 | 푸르듀 파머 리미티드 | 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난 |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| CN1087725C (zh) * | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| UA73736C2 (en) * | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060074059A1 (en) | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| RS51304B (sr) * | 2005-06-09 | 2010-12-31 | Euro-Celtique S.A. | Farmaceutske kompozicije neuroaktivnog steroida i njihova upotreba |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| US10577390B2 (en) * | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ME03809B (me) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| CN105985396A (zh) * | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| EP4155314A1 (en) * | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| AU2019406803B2 (en) | 2018-12-17 | 2025-04-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2023539125A (ja) | 2020-08-20 | 2023-09-13 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
-
2019
- 2019-12-17 AU AU2019406803A patent/AU2019406803B2/en active Active
- 2019-12-17 US US17/415,667 patent/US12325726B2/en active Active
- 2019-12-17 IL IL283960A patent/IL283960B2/en unknown
- 2019-12-17 CA CA3121636A patent/CA3121636A1/en active Pending
- 2019-12-17 MX MX2021007142A patent/MX2021007142A/es unknown
- 2019-12-17 BR BR112021011765-2A patent/BR112021011765A2/pt unknown
- 2019-12-17 KR KR1020217022377A patent/KR102931436B1/ko active Active
- 2019-12-17 EP EP19899589.6A patent/EP3897656A4/en active Pending
- 2019-12-17 CN CN201980083634.9A patent/CN113226326B/zh active Active
- 2019-12-17 JP JP2021534641A patent/JP7645797B2/ja active Active
- 2019-12-17 WO PCT/US2019/066923 patent/WO2020131918A1/en not_active Ceased